세계의 브랜드 제네릭 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 약제 클래스별, 용도별, 유통 채널별, 지역별, 경쟁별(2020-2030년)
Branded Generics Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Drug Class, By Application, By Distribution Channel, By Region & Competition, 2020-2030F
상품코드:1697986
리서치사:TechSci Research
발행일:2025년 03월
페이지 정보:영문 190 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
브랜드 제네릭 세계 시장 규모는 2024년 2,614억 1,000만 달러로 평가되었고, 2030년까지 6.20%의 연평균 복합 성장률(CAGR)을 나타내며 예측 기간 동안 괄목할 만한 성장이 예상됩니다.
브랜드 제네릭은 다른 브랜드 이름으로 시장에 재출시되는 의약품을 말합니다. 이러한 의약품은 더 저렴하게 재출시되며, 약의 내용은 동일하지만 모양, 크기, 색상, 맛 등이 다를 수 있습니다. 이는 약이나 의약품의 특허가 만료되었기 때문입니다. 고혈압, 당뇨병, 요통, 갑상선, 관절염 등의 치료에 사용할 수 있는 의약품은 시장에 남아 경쟁에서 살아남기 위해 더 저렴한 비용으로 재출시됩니다. 그러나 중요한 것은 재출시되는 의약품에 변경이 가해져도 품질은 변하지 않는다는 것입니다. 의약품이 수행하는 기능은 전혀 손상되지 않습니다.
용도별(종양학, 심혈관질환, 신경질환, 급성 및 만성 통증, 소화기질환, 피부질환, 기타)
유통 채널별(병원 약국, 소매 약국, 온라인 약국)
지역별
기업별(2024년)
시장 맵
제6장 북미의 브랜드 제네릭 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 브랜드 제네릭 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
프랑스
독일
영국
이탈리아
스페인
제8장 아시아태평양의 브랜드 제네릭 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 남미의 브랜드 제네릭 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
아르헨티나
콜롬비아
제10장 중동 및 아프리카의 브랜드 제네릭 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
남아프리카공화국
사우디아라비아
아랍에미리트
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
최근 동향
인수합병(M&A)
제품 출시
제13장 세계의 브랜드 제네릭 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Teva Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals Inc.
Sanofi-Aventis.
Sun Pharmaceutical Industries Inc.
Dr Reddy's Laboratories Inc.
Endo International PLC.
GlaxoSmithKline LLC.
Pfizer Inc.
Viatris Inc.
Apotex Inc.
제16장 전략적 제안
제17장 리서치사에 대해 & 면책사항
LSH
영문 목차
영문목차
Global Branded Generics Market was valued at USD 261.41 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 6.20% through 2030. Branded generics are medicines or pharmaceutical drugs that have been re-released on the market under a different brand name. These are re-released at a lesser cost, and the shape, size, colour, and flavour may differ, even though the medication remains the same. This is due to the fact that the medicine's or pharmaceutical drug's patent has expired. Drugs that can be used to treat hypertension, diabetes, back pain, thyroid, and arthritis, among other conditions, are re-released at cheaper costs in order to stay in the market and survive competition. However, it is important to highlight that, despite the alterations made in the re-release of the drug, the quality remains the same. The functions that the medicine would accomplish are not compromised in any way.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 261.41 Billion
Market Size 2030
USD 375.90 Billion
CAGR 2025-2030
6.20%
Fastest Growing Segment
Online Pharmacy
Largest Market
North America
Key Market Drivers
Increasing Prevalence of Chronic Diseases
The rising prevalence of chronic diseases is a major driving force behind the expansion of the Global Branded Generics Market. Approximately 9 million people succumb to cancer annually, while 4 million deaths are attributed to chronic respiratory diseases like asthma and COPD, and another 2 million result from diabetes-related complications. However, the global distribution of disease burden and access to advanced healthcare solutions remains highly uneven, with disparities particularly evident in low- and middle-income regions where medical infrastructure, early diagnostics, and treatment accessibility are significantly limited. With a growing global disease burden, healthcare systems and consumers are increasingly turning to cost-effective and reliable treatment options, making branded generics a preferred choice. Chronic diseases such as cardiovascular diseases (CVDs), diabetes, cancer, respiratory disorders, and arthritis are becoming more prevalent due to factors such as aging populations, unhealthy lifestyles, and environmental changes. According to the World Health Organization (WHO), non-communicable diseases (NCDs) account for nearly 74% of all global deaths, highlighting the urgent need for long-term treatment solutions. Increased demand for continuous medication supply for long-term disease management. Greater emphasis on cost-effective treatment alternatives, making branded generics a viable solution. Higher healthcare spending by governments and private insurers to address chronic disease care.
Key Market Challenges
Regulatory Hurdles
Generic medications, including branded generics, need to go through regulatory approval processes to ensure their safety, quality, and efficacy. Delays or complexities in the approval process can slow down the introduction of new branded generic products to the market. Regulatory authorities often have strict requirements for demonstrating the bioequivalence of branded generics to their branded counterparts. Meeting these requirements can be challenging and time-consuming, potentially causing delays in market entry. Regulatory challenges can arise when dealing with the patents of the original branded drugs. Patent disputes and legal battles can delay or prevent the launch of branded generics even after the patent has expired. Different countries have varying regulatory frameworks and requirements for generic medications. Navigating these diverse regulations can be complex for pharmaceutical companies looking to market branded generics globally. Ensuring consistent quality and adherence to manufacturing standards is crucial for the acceptance of generic medications. Regulatory hurdles related to quality control can affect the perception and trust of healthcare professionals and patients in branded generics. Some regulatory systems offer periods of data exclusivity or market exclusivity for innovator drugs, which can delay the entry of generic alternatives. This can hinder the availability of branded generics, especially in markets with longer exclusivity periods.
Key Market Trends
Advancements in Digital Health Integration
Digital health technologies can improve patient engagement by providing tools for medication reminders, tracking, and adherence. Branded generics, as more affordable alternatives, can benefit from increased patient engagement, leading to improved treatment outcomes and patient loyalty. Branded generics are often used for chronic disease management. Digital health solutions enable remote monitoring of patients' health conditions, which is particularly useful for managing chronic diseases. This integration can enhance patient compliance with medication regimens, contributing to the growth of the market. Digital health platforms can facilitate telemedicine consultations, where physicians can remotely diagnose and prescribe medications, including branded generics. This can increase the accessibility of these medications to patients, especially in regions with limited healthcare infrastructure. Digital health solutions can enable personalized treatment plans based on patient data and health metrics. Branded generics can be tailored to fit individual patient needs, resulting in better treatment outcomes and patient satisfaction. Digital health integration can improve awareness of branded generics among patients and healthcare providers. Through digital platforms, manufacturers can educate users about the benefits, availability, and cost savings associated with branded generics. Pharmaceutical companies can use data analytics to gain insights into market trends, patient preferences, and healthcare utilization patterns. This information can guide marketing strategies and product positioning for branded generics.
Key Market Players
Teva Pharmaceutical Industries Ltd.
Lupin Pharmaceuticals Inc.
Sanofi-Aventis.
Sun Pharmaceutical Industries Inc.
Dr Reddy's Laboratories Inc.
Endo International PLC.
GlaxoSmithKline LLC.
Pfizer Inc.
Viatris Inc.
Apotex Inc.
Report Scope:
In this report, the Global Branded Generics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Branded Generics Market, By Drug Class:
Alkylating Agents
Antimetabolites
Hormones
Anti - Hypertensive
Lipid Lowering Drugs
Antidepressant
Antipsychotics
Antiepileptics
Others
Branded Generics Market, By Application:
Oncology
Cardiovascular Diseases
Neurological Diseases
Acute & Chronic Pain
Gastrointestinal Diseases
Dermatological Diseases
Others
Branded Generics Market, By Distribution Channel:
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Branded Generics Market, By Region:
North America
United States
Canada
Mexico
Europe
France
United Kingdom
Italy
Germany
Spain
Asia-Pacific
China
India
Japan
Australia
South Korea
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Branded Generics Market.
Available Customizations:
Global Branded Generics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Branded Generics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
5.2.3. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Branded Generics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class (Alkylating Agents, Antimetabolites, Hormones, Anti - Hypertensive, Lipid Lowering Drugs, Antidepressants, Antipsychotics, Antiepileptics, Others)
